KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Income towards Parent Company (2017 - 2025)

Historic Income towards Parent Company for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Income towards Parent Company fell 12898.19% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 6147.43%. This contributed to the annual value of $426.9 million for FY2024, which is 15462.08% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Income towards Parent Company is -$30.7 million, which was down 12898.19% from $240.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Income towards Parent Company's 5-year high stood at $240.5 million during Q2 2025, with a 5-year trough of -$57.9 million in Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Income towards Parent Company averaged around $56.2 million, with its median value being $40.4 million (2023).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 44001.64% in 2021, then soared by 828273.09% in 2023.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Income towards Parent Company stood at -$57.9 million in 2021, then soared by 99.57% to -$249000.0 in 2022, then surged by 8282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 124.61% to -$30.7 million in 2025.
  • Its Income towards Parent Company was -$30.7 million in Q3 2025, compared to $240.5 million in Q2 2025 and $185.7 million in Q1 2025.